Federal multidistrict litigation tracker

MDL 3094 Update — Ozempic / GLP-1 Lawsuit

In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation. Counts are monthly JPML snapshots and can change between reports.

Lawsuit status — October 2026

Ozempic / GLP-1 Lawsuit

Verified October 23, 2026

MDL: MDL-3094
Court: E.D. Pa.
Judge: Judge Karen Spencer Marston
Pending cases: 4,025; Count as of October 1, 2026 · Source; +3 since prior report
Current phase: Rule 702 closing arguments set for October 13, 2026; no ruling yet
Settlement status: No public settlement program identified
Latest development: The public MDL-3094 orders page, checked October 23, lists the October 8 scheduling order for Rule 702 closing arguments on Cross Cutting Issues 2 and 3 but no ruling on those motions.
Next major event: No future public court date is currently verified in this record.

What changed this month?

●The public MDL-3094 orders page, checked October 23, lists the October 8 scheduling order for Rule 702 closing arguments on Cross Cutting Issues 2 and 3 but no ruling on those motions. Source
●An October 8 scheduling order sets closing arguments on the pending Rule 702 motions for Cross Cutting Issues 2 and 3 for October 13, 2026. The public orders page reviewed October 11 shows no Rule 702 ruling, bellwether trial date or settlement program. Source
●JPML reports 4,025 pending actions in MDL-3094 on October 1, 2026, up 3 from 4,022 on September 1; 4,139 total historical actions are reported separately. Source
●The separate MDL-3163 has 247 pending actions as of October 1, 2026, compared with 216 on September 1. Source
●JPML reports 4,022 pending actions on September 1, 2026, compared with 3,928 on August 3; 4,056 total historical actions are reported separately. Source

MDL details

Created: February 2, 2024
Pending: 4,025
Total actions filed: 4,139
Monthly change: +3

Defendants named in the tracked record

Novo Nordisk (Ozempic, Wegovy, Rybelsus, Saxenda); Eli Lilly (Mounjaro, Zepbound, Trulicity). Defendants dispute the allegations.

Historical case counts

Report	Pending	Total filed
October 1, 2026	4,025	4,139
September 1, 2026	4,022	4,056
August 3, 2026	3,928	3,962

What the litigation alleges

The tracked claims concern prescription drug injury claim (federal mdl), including gastroparesis and severe gastrointestinal injuries. These are allegations; defendants dispute liability and causation.

Stage and bellwether status

The court held the Rule 702 evidentiary hearing on September 14–18, 2026. An October 8 scheduling order sets closing arguments on the pending Rule 702 motions for Cross Cutting Issues 2 and 3 for October 13, 2026, in place of that day's status conference. No Rule 702 ruling appears on the public orders page reviewed October 11. This is an expert-evidence proceeding, not a bellwether trial, and NAION vision-loss claims are coordinated separately in MDL-3163.

Settlement status

The Eastern District of Pennsylvania public MDL orders reviewed October 11, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The Rule 702 proceeding concerns expert evidence, not settlement eligibility or an individual award.

Individual claims: The Eastern District of Pennsylvania public MDL orders reviewed October 11, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The Rule 702 proceeding concerns expert evidence, not settlement eligibility or an individual award.